The potential of nanomedicine therapies to treat neovascular disease in the retina by Farjo, Krysten M & Ma, Jian-xing
REVIEW Open Access
The potential of nanomedicine therapies to treat
neovascular disease in the retina
Krysten M Farjo, Jian-xing Ma
*
Abstract
Neovascular disease in the retina is the leading cause of blindness in all age groups. Thus, there is a great need to
develop effective therapeutic agents to inhibit and prevent neovascularization in the retina. Over the past decade,
anti-VEGF therapeutic agents have entered the clinic for the treatment of neovascular retinal disease, and these
agents have been effective for slowing and preventing the progression of neovascularization. However, the thera-
peutic benefits of anti-VEGF therapy can be diminished by the need for prolonged treatment regimens of repeated
intravitreal injections, which can lead to complications such as endophthalmitis, retinal tears, and retinal detach-
ment. Recent advances in nanoparticle-based drug delivery systems offer the opportunity to improve bioactivity
and prolong bioavailability of drugs in the retina to reduce the risks associated with treating neovascular disease.
This article reviews recent advances in the development of nanoparticle-based drug delivery systems which could
be utilized to improve the treatment of neovascular disease in the retina.
Introduction
Retinopathy of prematurity (ROP), diabetic retinopathy
(DR), and age-related macular degeneration (AMD), are
the leading causes of blindness in infants, working-age
adults, and the elderly, respectively [1-4]. These retinal
diseases of varying etiology culminate with the develop-
ment of pathogenic neovascularization, which disrupts
retinal structure and function, causing irreversible vision
loss. Although we understand much of the molecular
mechanisms of neovascularization and have identified
molecular targets and effective treatment options, sus-
taining safe and efficient drug delivery to the retina
remains the primary obstacle to effectively treating neo-
vascular disease in the retina. This is due to the inher-
ent, isolated nature of the eye and the retina, which
possesses a blood-retinal-barrier (BRB) to limit the dif-
fusion of substances from the blood into the retina [5,6].
The retina consists of seven layers of neuronal cells,
including the photoreceptor cells which convert light sti-
muli into electrical signals that are sent through the
other retinal neuronal cells to the optic nerve in order for
visual perception to occur (Figure 1A). Adjacent to the
photoreceptor cells, there is a monolayer of retinal pig-
ment epithelial (RPE) cells. On the other side of the RPE
cell monolayer, there is a basement membrane of extra-
cellular matrix molecules known as Bruch’s membrane,
which separates the RPE from the choroidal vasculature.
There are two levels of the BRB, the outer BRB (oBRB),
which is formed by intercellular tight junctions in the
RPE monolayer to restrict the passage of molecules from
the choroidal blood supply into the neural retina, and the
inner BRB (iBRB), which is formed by a monolayer of
specialized non-fenestrated endothelial cells that form
tight junctions within the retinal capillaries to prevent
widespread diffusion of substances into the retina [5,6].
The BRB is a major obstacle for drug delivery to treat ret-
inal diseases [7]. Systemic drug dosing, via oral, intrave-
nous, subcutaneous, or intraperitoneal administration is
n o tv e r ye f f e c t i v ef o rd r u gd e livery to the retina, since
only 1-2% of the drug reaches the RPE and neural retina
[8,9]. Likewise, topical administration of drugs on the
ocular surface in the form of eye drops or ointments is
also inefficient for drug delivery to the retina. Thus,
intravitreal (IVT) injection is most commonly used for
drug administration to treat retinal disease. Although
IVT injection can efficiently deliver drugs to the retina
and RPE, prolonged treatment for chronic diseases often
requires repeated injections, which can lead to severe
complications, such as infections and retinal detachment.
DR and AMD are chronic, progressive diseases that
lead to neovascularization within the retina. Therapeutic
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cularization in DR and AMD, but the therapeutic bene-
fits can be diminished by inefficient drug delivery and
the limited duration of drug bioavailability, which
requires prolonged treatment regimens of repeated IVT
injections [10,11]. Thus, improved drug delivery systems
must be developed to treat neovascularization in DR
and AMD. This article reviews the latest approaches to
target and treat neovascular disease in the retina, with
specific emphasis on recent preclinical studies in animal
models and early-phase clinical trials aimed at develop-
ing nanomedicine modalities for more efficient and sus-
tained delivery of therapeutic agents to the retina.
Cellular and Molecular Mechanisms of Pathogenic
Neovascularization in the Retina
There are two types of neovascularization that occur in
the retina and cause vision loss: retinal neovascularization
(RNV) in which new vessels sprout from the retinal capil-
laries and invade the vitreous and neural retinal layers,
and choroidal neovascularization (CNV) in which new ves-
sels sprout from the choroidal vasculature and invade the
subretinal space (Figure 1B and 1C). RNV can occur in
both ROP and proliferative DR [1-3,12], whereas CNV can
occur in patients with AMD [13,14]. Although RNV and
CNV originate from different vascular networks and
invade different layers of the retina, shared molecular
mechanisms promote the progression of both.
In the pathogenesis of AMD, RPE cell function is
impaired, which causes toxic cellular debris to accumu-
late intracellularly and underneath the basal surface of
the RPE cell layer in the Bruch’s membrane. Subse-
quently, RPE cell death can occur in patches known as
geographic atrophy, and compromise the oBRB. At sites
of geographic atrophy, ischemia and inflammation can
promote CNV into the subretinal space. The newly
Figure 1 Schematic representation of the retina and sites of pathogenic neovascularization. (A) Illustration of the eye, with the anterior
segment consisting primarily of the lens, iris, and cornea and the posterior segment consisting primarily of the vitreous and retina. The small
box highlights the location of the retinal tissue which lines the back of the eye and is diagramed in more detail. The retina is stratified into
highly ordered layers as labeled in the picture. (B) Retinal neovascularization occurs when retinal capillaries pass through the inner limiting
membrane and invade the retinal tissue, primarily in the ganglion cell layer. (C) Choroidal neovascularization occurs when choroidal capillaries
pass through Bruch’s membrane and invade the RPE and subretinal space.
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and damage, resulting in photoreceptor cell death and
permanent vision loss.
In DR, high blood glucose levels cause oxidative stress
in endothelial cells, which results in cellular metabolic
dysfunction and leads to retinal capillary basement mem-
brane thickening. This initiates pericyte and endothelial
cell death, resulting in breakdown of the iBRB. The loss
of retinal capillary function causes vascular leakage and
inflammation, as well as retinal ischemia, which pro-
motes RNV and leads to irreversible vision loss.
ROP occurs in premature infants who are exposed to
relative hyperoxia before the angiogenic phase of retinal
development is complete [12]. This is problematic, since
the angiogenic phase of retinal development is normally
driven by hypoxia in utero [12]. Thus, normal angio-
genic retinal development is disturbed in ROP, causing
vaso-obliteration and the formation of a largely avascu-
lar retina [12]. In the absence of an adequate blood sup-
ply, the avascular retina is ischemic, which promotes
destructive RNV, and can lead to retinal detachment
and the formation of scar tissue, resulting in permanent
vision loss [12].
Retinal ischemia is a common component of the
pathogenesis of both CNV and RNV. Ischemia causes
cellular hypoxia, which activates cellular signaling path-
ways to up-regulate the expression of angiogenic stimu-
lators, such as vascular endothelial growth factor
(VEGF) [15]. VEGF is a secreted glycoprotein with
potent pro-angiogenic activity. VEGF binds to VEGF
receptors (VEGFR) on endothelial cells to stimulate cell
proliferation and migration. Numerous studies have
shown that VEGF is up-regulated during the pathogen-
esis of CNV and RNV, and that VEGF is a key mediator
of CNV and RNV pathogenesis [15].
Disrupted Balance of Angiogenic and Anti-Angiogenic
Factors in RNV and CNV
The normal retina expresses a low amount of VEGF in
the RPE, and high levels of angiogenic inhibitors, such
as pigment epithelium-derived factor (PEDF) [16,17].
PEDF is a secreted glycoprotein that belongs to the ser-
ine proteinase inhibitor (SERPIN) family, but does not
have SERPIN activity. PEDF has potent anti-angiogenic
activity and counteracts the effects of VEGF [18]. Thus,
in the normal retinal homeostasis, the balance between
pro- and anti-angiogenic factors tips in favor of angio-
genic inhibition. This balance is disrupted during the
pathogenesis of both CNV and RNV, as retinal ischemia
promotes the up-regulation of VEGF expression and the
down-regulation of PEDF expression, creating an
increased VEGF/PEDF ratio that strongly promotes
angiogenic stimulation during CNV and RNV [16,17,19].
Therapeutic interventions that either decrease the
VEGF/PEDF ratio or inhibit VEGF activity can signifi-
cantly inhibit CNV and RNV progression [11,18,20]. In
rodent models, IVT injection of either recombinant
PEDF protein or an adeno-associated viral plasmid
expressing PEDF effectively decreases the VEGF/PEDF
ratio and significantly reduces RNV and CNV [18,21].
VEGF is the primary angiogenic stimulator in CNV and
RNV, which has been highlighted by the clinical success
of therapeutic agents that inhibit VEGF activity for the
treatment of AMD and DR [11,20]. However, anti-VEGF
therapies have reduced efficacy during long-term treat-
ment regimens. In a clinical study of patients with
AMD, the efficacy of a single IVT injection of the anti-
VEGF antibody Avastin® decreased to 50% of the initial
dose response by the third IVT injection dose [22]. This
phenomenon, known as tachyphylaxis, can contribute to
the recurrence of neovascularization after anti-VEGF
therapy.
Other angiogenic stimulators, such as platelet-derived
growth factor (PDGF) and fibroblast growth factor
(FGF) can also promote the pathogenesis of CNV and
RNV, but therapeutically targeting either PDGF or FGF
alone is not as effective as targeting VEGF activity;
Nevertheless, studies suggest that combining PDGF or
FGF inhibitors with VEGF inhibitors can have synergis-
tic therapeutic effects in reducing the pathogenesis of
CNV [23,24]. In the future, combining therapies that
target more than one angiogenic factor are likely to
improve clinical outcome for AMD and DR patients,
In addition to PEDF, other angiogenic inhibitors are
also expressed in the retina/RPE and have been impli-
cated to play a role in the pathogenesis of CNV and
RNV. For instance, another SERPIN family member,
SERPINA3K, is an angiogenic inhibitor expressed in the
normal retina that is down-regulated during the patho-
genesis of RNV in DR [25]. In a rodent model of RNV,
IVT injection of recombinant SERPINA3K protein
decreased hypoxia-induced VEGF up-regulation and sig-
nificantly reduced RNV and vascular leakage [26,27].
Thrombopsondins (TSPs) are a type of secreted glyco-
protein expressed by endothelial cells and RPE. TSP1
and TSP2 can inhibit endothelial cell proliferation and
migration in vitro [28]. TSP1 is expressed in human
RPE, and its expression is down-regulated in AMD
[19,29]. Tsp1
-/- mice have increased retinal vascular den-
sity [30], whereas overexpression of TSP1 significantly
inhibits RNV in the oxygen-induced retinopathy (OIR)
mouse model [31]. Conversely, one study demonstrated
that TSP1 stimulates VEGF and FGF2 secretion from
cultured RPE cells [32], and another study found that
TSP1 is necessary for PDGFB-mediated stimulation of
pericyte proliferation and migration [33]. Thus, TSPs
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angiogenic inhibitors.
Several angiogenic inhibitors are generated from the
proteolytic cleavage products of native proteins, which
display no angiogenesis-related activity prior to cleavage.
One notable example is plasminogen, a pro-enzyme that
is cleaved to generate the fibrinolytic enzyme plasmin.
Additional cleavage of plasmin produces peptides with
anti-angiogenic activity, including angiostatin and krin-
gle 5 (K5). Angiostatin is a 38 kDa polypeptide which
contains the first four triple disulfide bond-linked loops
of plasminogen known as kringle domains [34]. Systemic
(subcutaneous) or IVT injection of angiostatin reduces
CNV, RNV and vascular leakage in rodent models
[35-37]. K5 is the fifth kringle domain of plasminogen,
consisting of only 80 amino acids. K5 is more potent
than angiostatin for inhibiting bFGF-stimulated
endothelial cell proliferation in vitro (ED50 =5 0n Mv s .
140 nM, respectively) [38]. In rodent models, IVT injec-
tion of either recombinant K5 protein or adeno-asso-
ciated viral plasmid expressing K5 significantly decreases
VEGF expression, increases PEDF expression, and
reduces RNV [39-41].
Another group of angiogenic inhibitors, named vasoin-
hibins, are generated by the proteolytic cleavage of pro-
lactin, growth hormone, or placental lactogen. Prolactin
and prolactin-derived vasoinhibins are present in the
retina [42], and prolactin-derived vasoinhibins can block
VEGF-induced vasopermeability in rats with DR [43]. In
rodent models, IVT injection of either antibodies against
vasoinhibins or siRNA against prolactin causes retinal
angiogenesis and vasodilation [42], whereas injection of
recombinant vasoinhibin can suppress RNV [44]. These
data suggest that prolactin-derived vasoinhibins are
important angiogenic inhibitors in the retina.
Extracellular matrix (ECM) proteins, which are abun-
dant in the retinal capillary basement membrane as well
as the Bruch’s membrane adjacent to the choriocapil-
laris, can also be cleaved to generate angiogenic inhibi-
tors. The native or un-cleaved forms of these basement
membrane proteins display no angiogenesis-related
activity. This is intriguing, since the proteolytic digestion
of the capillary basement membrane necessarily pre-
cedes angiogenic sprouting of new blood vessels. This
implies that angiogenic inhibitors may be produced dur-
ing early angiogenic sprouting in order to counterba-
lance angiogenic stimulators like VEGF and limit the
extent of neovascularization. The most well-studied
ECM-derived angiogenic inhibitor is endostatin, a 20
kDa C-terminal fragment derived from collagen XVIII
alpha 1 (Col18a1) [45]. Endostatin is expressed in the
human RPE [46], and its expression is decreased in
AMD [19]. In a mouse model of laser-induced CNV,
Col18a1
-/- mice developed 3-fold larger CNV lesions
than wild-type mice [47]. Moreover, intraperitoneal (i.p.)
injection of recombinant endostatin significantly
reduced CNV lesion size [47]. Recombinant endostatin
was the first endogenous angiogenic inhibitor to begin
clinical trials as an anti-tumor therapy [48], and
although it was non-toxic, it lacked potent efficacy as a
monotherapy [48,49]. Since then, both endostatin and
an N-terminally tagged version of endostatin known as
Endostar, have been combined with chemotherapeutic
agents to increase tumor regression in clinical trials
[50]. In 2005, Endostar was approved for the treatment
of non-small-cell lung cancer in China, but it has yet to
gain approval from the U.S. Food and Drug Administra-
tion (FDA). Another ECM-derived angiogenic inhibitor,
tumstatin, is generated from the cleavage of collagen
type IV. Tumstatin binds to avb3 integrin, which is
highly expressed on the cell surface of proliferative, neo-
vascular endothelial cells. Tumstatin can significantly
inhibit endothelial cell proliferation in vitro [51], sug-
gesting that it could function to reduce RNV and CNV,
a l t h o u g ht h ea n g i o g e n i cr o l eo ft u m s t a t i nh a sn o ty e t
been investigated in animal models of RNV or CNV.
Current Treatment Options for RNV and CNV
A common treatment for DR is laser-induced photocoa-
gulation, in which a laser is used to alleviate hypoxia in
the retina and attenuate RNV [52]. Although photocoa-
gulation can stabilize vision and reduce the risk of
future vision loss in many patients, there are significant
risks associated with photocoagulation therapy, since the
laser treatment alone can cause damage to the retina
and permanently impair vision [52]. Furthermore, laser
photocoagulation therapy does not stop the progression
of DR in all patients. A similar, but safer laser-based
method, photodynamic therapy (PDT), was the first
FDA-approved therapy for the treatment of neovascular
AMD. PDT utilizes a photo-activatable drug, verteporfin
(Visudyne®, QLT Ophthalmics/Novartis AG), which is
administered intravenously [53]. Vertoporfin collects in
the choriocapillaris, and a low-energy laser beam is
focused onto CNV lesions to activate verteporfin, which
will induce blood clot formation to seal off abnormal
neovascular blood vessels [53]. PDT cannot regress
CNV lesions, but it can reduce the progression of CNV,
although PDT must be repeated to sustain inhibition of
vascular leakage [54].
A plethora of studies over the past decade have inves-
tigated the development of therapeutic agents that
directly target the molecular mechanisms of angiogen-
esis. VEGF is the primary angiogenic stimulator in the
pathogenesis of RNV and CNV [15]. Thus, several ther-
apeutic agents have been designed to specifically inhibit
VEGF activity, and such drugs have had clinical success
in the treatment of DR and AMD [15]. In 2004,
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to obtain FDA approval for the treatment of CNV in
AMD [55]. Macugen® is a 50 kDa RNA aptamer that
binds to and inhibits VEGF [11,55]. Also in 2004, a
humanized monoclonal anti-VEGF antibody, beva-
cizumab (Avastin®, Genentech) was approved for anti-
angiogenic therapy in cancer [56]. Avastin® is still in
clinical trials for the treatment of AMD and DR, but it
is routinely prescribed off-label for AMD patients
[11,56]. A smaller fragment of the bevacizumab anti-
body, ranibizumab (Lucentis®, Genentech) was FDA-
approved specifically for the treatment of AMD in 2006,
and is undergoing further clinical trials for the treat-
ment of DR [11,57]. Several clinical trials have shown
that anti-VEGF therapeutic agents are more effective
than PDT in maintaining and restoring visual acuity and
reducing CNV progression in patients with AMD
[10,56]. Thus, other inhibitors of VEGF activity are also
in development, including a soluble VEGFR mimetic,
aflibercept (VEGF Trap-Eye™, Regeneron), and a siRNA
that inhibits VEGF expression, bevasiranib (Cand5™,
OPKO Health Inc.) [11]. The VEGF Trap-Eye™ is cur-
rently in Phase III clinical trials, and preliminary results
have shown that it has been an effective treatment for
CNV in AMD [58]. Clinical trials investigating the use
of Cand5™ as a monotherapy were terminated in 2009
because Cand5™ therapy was less effective than Lucentis®
therapy; however, Cand5™ is now in a clinical trial as a
combination therapy administered in conjunction with
Lucentis [11].
Although these anti-VEGF therapies have been effec-
tive for slowing disease progression and reducing the
risk of vision loss due to AMD and DR, these therapies
are limited by the need for burdensome and risky IVT
injections, which must be repeated every 4-12 weeks in
order to sustain therapeutic levels of the drugs in the
retina [10,11]. IVT injection can lead to vision-threaten-
ing complications, such as endophthalmitis, cataract,
retinal tears, and retinal detachment [10,59]. Thus, more
effective drug delivery systems are desired to circumvent
the need for IVT injection or at least reduce the fre-
quency of IVT injections to thereby improve safety and
increase patient compliance and patient outcome.
Developing Superior Therapeutic Agents with
Nanotechnology
Nanotechnology offers the opportunity to create new
drug delivery systems (DDS) to improve drug efficacy
and safety for the treatment of neovascular disease in
the retina. Nanotechnology has been defined as the
design, characterization, production, and application of
structures, devices, and systems by controlled manipula-
tion of size and shape at the nanometer scale (atomic,
molecular, and macromolecular scale) that produces
structures, devices, and systems with at least one novel
or superior characteristic or property [60]. Nanotechnol-
ogy classically refers to matter in the size range of 1-100
nm, but it is often extended to include materials below
1 μm in size. The small size of nanotechnology materials
could be especially useful for retinal drug delivery of
systemically-administered drugs, which can be hindered
by the BRB. Several studies have already demonstrated
that some types of nanoparticles can cross the BRB to
deliver therapeutics to the retina without exerting
obvious cytotoxicity [61-63]. Furthermore, nanotechnol-
ogy can be used to optimize drug formulations to
increase drug solubility and alter pharmacokinetics to
sustain drug release and thereby prolong bioavailability.
In addition, the diverse platforms of nanotechnology can
also be utilized to develop more sophisticated, cell-
targeted therapies and to combine different drugs into
one nanotherapeutic agent for synergistic therapeutic
benefits.
Nanotechnology could be harnessed to reformulate
anti-VEGF therapies for prolonged bioavailability and
targeted delivery to neovascular lesions. However, nano-
technology-based DDS are in early stages of develop-
ment, and reformulation of anti-VEGF therapies with
nanotechnology-based DDS would require that new
anti-VEGF “nanotherapies” be reevaluated for safety
and efficacy in clinical trials, which is costly and time-
consuming. Nevertheless, numerous preclinical studies
suggest that nanotechnology-based DDS can address
and overcome many of the challenges of retinal drug
delivery to greatly improve therapeutic outcomes. This
should encourage pharmaceutical scientists to co-
develop nanotechnology-based DDS for new anti-neo-
vascular therapeutic agents during preclinical develop-
ment in order to generate superior nanotherapeutic
agents for clinical trials.
Nanoparticle Platforms for Drug Delivery Systems
There is a diverse arsenal of nanoparticle systems avail-
able for the development of both simple and sophisti-
cated nanotherapeutic agents to target neovascular
disease in the retina. Nanoparticle platforms include
synthetic and natural lipid-, polymer-, polypeptide-, and
polysaccharide-based systems, as well as metallic nano-
particulates, such as gold [64-67]. Lipid-based nanoparti-
cles can be used to generate liposomes, which consist of
a phospholipid bilayer membrane that encapsulates
cargo molecules [68]. Since naturally-occurring phos-
pholipids are often used to generate liposomes, they are
generally found to be biocompatible, non-toxic, and
non-immunogenic. Liposomes can encapsulate either
hydrophobic or hydrophilic molecules with high effi-
ciency. Several liposome-based nanoparticle DDS have
been FDA-approved for clinical use [68]. However,
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be improved by generating hybrid liposome-polymer
nanoparticles. The polymeric compound polyethylene
glycol (PEG) is most commonly used for this purpose.
PEG is the most widely used polymeric nanoparticle sys-
tem, and it can greatly extend the bioavailability of ther-
apeutic agents.
The polymers polylactide (PLA) and polyglycolide
(PGA) are also widely used for nanoparticle DDS. PLA
and PGA are often mixed to generate the copolymer
Poly(D,L-lactide-co-glycolide) (PLGA) [69,70]. Various
ratios of PLA/PGA can be utilized to generate PLGA
nanoparticles which have distinct and well-characterized
rates of degradation [69]. PLGA is biocompatible, biode-
gradable, non-toxic, and non-immunogenic, and thus,
numerous PLGA-containing therapeutic agents have
been approved by the FDA [71]. PLGA-based nanoparti-
cle DDS have been extensively studied for gene therapy
applications, as PLGA has been shown to mediate endo-
lysosomal escape, which reduces DNA plasmid degrada-
tion and increases delivery of DNA plasmids to the
nuclear compartment [72].
In recent years, polymeric dendrimers have also
been developed as nanoparticle DDS. Dendrimers are
globular macromolecules which contain a central core
element from which highly-branched structures ema-
nate [73]. Dendrimer branches can be extended by
stepwise synthesis, which allows for precise control of
dendrimer structure, molecular weight, solubility, size,
and shape. Thus, dendrimers are well-defined in size
and composition compared to other nanoparticle DDS
[73]. In addition, natural polymers, such as polypep-
tides and polysaccharides can also be used for nano-
particle DDS [67]. Polypeptide-based nanoparticles are
most commonly generated using either albumin or
poly-L-lysine, whereas polysaccharides, such as hya-
luronic acid, heparin, chitosan, and cyclodextrin, can
be formulated into nanoparticles alone or in combina-
tion with lipid-based or polymer-based nanoparticle
platforms [64,67,74].
Metals, such as gold, silver, and platinum, can also be
used for nanoparticle DDS. Gold is most commonly
used, as it is inert, non-toxic, and non-immunogenic. A
recent study showed that gold nanoparticles of 20 nm
can pass through the BRB and exhibit no retinal toxicity,
suggesting that gold nanoparticles could be used to
safely and effectively deliver therapeutic agents to the
retina [62]. Interestingly, naked gold nanoparticles have
intrinsic anti-angiogenic activity. Moreover, gold nano-
particles conjugated with glycosaminoglycans have
enhanced anti-angiogenic activity [75,76]. This phenom-
enon has also been observed in chitosan nanoparticles
and sixth generation poly-L-lysine dendrimers, which
possess inherent anti-angiogenic activity [77,78]. These
observations warrant further investigation into the use
of such nanoparticles for neovascular disease.
Development of Nanoparticle DDS to Treat Neovascular
Disease in the Retina
Promising anti-neovascular therapeutic agents include
gene therapy vectors, peptide-based inhibitors, antibo-
dies, oligonucleotide aptamers, and small molecules.
Some of these therapeutic agents have been combined
with nanotechnology-based DDS in preclinical studies,
resulting in increased and prolonged bioavailability,
enhanced cell targeting, and overall increased therapeu-
tic benefit compared to conventional DDS in animal
models. The potential applications of nanoparticle-based
DDS for the treatment of retinal neovascular disease are
highlighted in the following sections.
Nanoparticles in Gene Therapy
Chronic and progressive retinal diseases, such as AMD
and DR, require sustained delivery of therapeutic agents
to the retina. As mentioned previously, although anti-
angiogenic therapy with anti-VEGF agents has improved
the treatment of AMD, these agents must be delivered
to the retina by IVT injection every 4-12 weeks to main-
tain therapeutic benefits [10,11]. Gene therapy-based
delivery of anti-angiogenic factors could theoretically
provide significantly prolonged therapeutic benefits after
a single IVT injection.
The development of gene therapy vectors has surged
over the past 15-20 years, and gene therapy has shown
both significant successes and failures in the clinic
[79,80]. Viral vectors, such as recombinant adeno-asso-
ciated viral vector (rAAV), have been most commonly
used for gene therapy applications. However, there are
significant safety concerns regarding the use of rAAV for
gene therapy, as human clinical trials with rAAV have
lead to oncogenesis and fatal systemic inflammation
[79,81-83]. In addition to the potential for adverse immu-
nological responses, rAAV has a limited capacity for
insert DNA (< 5 kb) as well as limited cell tropism [79].
Nevertheless, recent human clinical trials in patients with
Leber’s congenital amourosis caused by null mutations in
RPE-specific protein 65 kDa (RPE65) have demonstrated
that a single IVT injection of rAAV that expresses RPE65
can mediate expression of RPE65 for up to 1.5 years and
improve vision without eliciting adverse immunological
responses [80,84,85]; however, a transient increase in
neutralizing antibodies to the rAAV capsid protein was
observed [80]. Although the rAAV-RPE65 gene therapy
results are hopeful at this point, the long-term safety and
efficacy remains to be determined. rAAV-mediated gene
therapy in the retina has been relatively safe thus far, due
to the BRB-mediated immune-privileged state of the
retina, although IVT injection of rAAV vectors in rats
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suggesting that rAAV vectors should be used with
caution.
As a potential treatment for CNV, a rAAV was gener-
ated to express recombinant human PEDF [21]. Periocu-
lar (scleral) injection of rAAV-PEDF resulted in
increased PEDF expression in the retina, RPE, and chor-
oid and resulted in a significant reduction in CNV
lesions in mouse and pig models [21,88]. In a recent
Phase I clinical trial, rAAV-PEDF was administered by a
single IVT injection to patients with neovascular AMD
(CNV) [89]. The injection resulted in transient intraocu-
lar inflammation and increased intraocular pressure in
25% and 21% of patients, respectively. No other adverse
inflammation occurred, suggesting the gene therapy was
reasonably safe. Depending on the rAAV-PEDF dosage,
between 50% and 71% of patients experienced either no
change or improvement in CNV lesion size at 6 months
post-injection. These results provide a proof-of-concept
that angiogenic inhibitors can be delivered to the retina/
R P Eb yg e n et h e r a p yv e c t o r s ;h o w e v e r ,t h eu s eo fn o n -
viral vectors could reduce or prevent the incidence of
intraocular inflammation observed with rAAV injection.
Non-viral DNA vectors offer a safe alternative to
rAAV-mediated gene therapy, as non-viral vectors are
non-immunogenic and non-toxic. Previously, the use of
non-viral vectors has been limited due to low transfec-
tion efficiency and increased susceptibility to nuclease
degradation. However, novel nanotechnology-based DDS
have offered new potential for the use of non-viral vec-
tors for gene therapy applications. Non-viral DNA vec-
tors as large as 20 kb can now be compacted into
nanoparticles of less than 25 nm in diameter, which
allows the DNA to pass through nuclear pores [90].
This greatly enhances the transfection efficiency of non-
viral vectors, especially in post-mitotic cells which could
not be transfected by conventional non-viral DNA vec-
tors [90-92]. Moreover, nanoparticle encapsulation also
prolongs vector half-life by protecting the DNA from
nuclease degradation.
In an effort to develop an efficient non-viral gene
therapy vector for the treatment of RNV, we recently
encapsulated a non-viral K5 expression plasmid into
PLGA:Chitosan nanoparticles to produce a K5 nanopar-
ticle expression vector (K5-NP) [93]. PLGA is a biocom-
patible, biodegradable polymer that is FDA-approved for
use in humans [70]. PLGA nanoparticles have previously
been shown to interact with the endo-lysosomal mem-
brane and escape from the endocytic pathway into the
cell cytosol, which may increase the delivery of PLGA
nanoparticles to the nucleus [72]. Thus, PLGA-based
nanoparticles are an attractive choice for gene therapy
applications. The K5-NP was administered by IVT injec-
tion into rat models of ischemia-induced RNV and
streptozotocin (STZ)-induced diabetes. We found that
the K5-NP mediated expression of K5 in the retina for
up to 4 weeks following a single IVT injection. The K5-
NP expression was primarily restricted to the ganglion
cell layer, with a high level of transfection efficiency. We
demonstrated that the K5-NP significantly reduced
ischemia-induced RNV, and decreased vascular leakage
in both STZ-induced diabetes and ischemia-induced
RNV [93]. The K5-NP prevented the up-regulation of
VEGF and ICAM-1 in diabetic retinas for up to 4 weeks
post-injection of the K5-NP. There was no detectable
toxicity associated with the K5-NP, as histological ana-
lyses demonstrated that retinal structure and thickness
was unaffected by K5-NP. Furthermore, the K5-NP did
not increase retinal apoptotic cells, and electroretinogra-
phy analyses showed that retinal physiology was normal
following K5-NP injection. These studies demonstrate
how nanoparticle-based DDS can facilitate non-viral
gene therapy. Moreover, the K5-NP is an example of
how gene therapy and nanotechnology can be combined
to generate superior nanotherapeutics for the potential
treatment of neovascular disease in the retina.
Peptide carriers can be incorporated into nanoparticles
to enhance cellular uptake and avoid endolysosomal traf-
ficking of cargo molecules, which may result in increased
nuclear targeting of gene therapy vectors [94-96]. Peptide
carriers include natural protein transduction domains
and synthetic cell-penetrating peptides, which have the
ability to traverse cell membranes without the use of
transporters or cell surface receptors [94]. Natural
protein transduction domains include the trans-activating
regulatory protein (TAT) of human immunodeficiency
virus and the VP22 protein from herpes simplex virus.
Based on the molecular modeling of natural pro-
tein transduction domains, synthetic cell-penetrating
peptides, such as Pep-1 and Pep-2 were developed. The
Pep-1 and Pep-2 peptides consist of only 21 amino acid
residues and contain 3 functionally distinct domains: a
hydrophobic tryptophan-rich motif for cell membrane
targeting, a hydrophilic lysine-rich domain derived from
the SV40 large T antigen nuclear localization sequence
which facilitates intracellular delivery, and a small linker
domain which includes a proline residue to allow for flex-
ibility [94]. Pep-1 and TAT peptides have been incorpo-
rated into nanoparticles to increase cellular and nuclear
uptake of cargo molecules [97-100]. TAT-conjugation
was able to increase nuclear targeting of 5 nm, but not
30 nm gold nanoparticles, suggesting that TAT-mediated
trafficking to the nuclear compartment is restricted
by nuclear pore dimensions [97-99].
Recently, a novel nanoparticle formulation was devel-
oped which compacts DNA to generate nanoparticles
which contain a single DNA plasmid [92]. These nano-
particles utilize a 30-mer polylysine peptide which
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terminal cysteine residue facilitates covalent bond for-
mation with 10 kDa PEG to generate PEGylated CK30
(CK30-PEG). Plasmid DNA is then mixed with CK30-
PEG to generate nanoparticles, and the size and shape
of the nanoparticles can be adjusted by using different
lysine amine counterions. Importantly, the minor dia-
meter of each nanoparticle can be restricted to less than
25 nm, which allows CK30-PEG nanoparticles to traffic
through nuclear pores [91,101]. This likely explains how
CK30-PEG DNA nanoparticles can mediate efficient
gene expression in post-mitotic cell types [91,92,102].
The cellular uptake and nuclear targeting of CK30-PEG
nanoparticles does not involve the endocytic pathway,
but appears to be mediated at least in part by binding to
nucleolin. Nucleolin is selectively expressed on the
plasma membrane of specific cell types, including post-
mitotic retinal cells [101,103].
To investigate the potential use of CK30-PEG nanopar-
ticles in retinal gene therapy, a reporter DNA plasmid
which expressed green fluorescent protein (GFP) under
the control of the cytomegalovirus promoter was com-
pacted into CK30-PEG nanoparticles, and administered
by IVT or subretinal (SRT) injection in mice [91]. SRT
injection of CK30-PEG-GFP nanoparticles produced sig-
nificant GFP expression in the RPE and retina, whereas
IVT injection yielded significant GFP expression in the
retina. Electroretinography analyses detected no abnorm-
alities in retinal physiology due to the CK30-PEG-DNA
nanoparticle injections. To t a lG F Pe x p r e s s i o ni nt h e
retina was dependent on the amount of CK30-PEG-DNA
nanoparticles injected. More recently, CK30-PEG nano-
particles were used to deliver a DNA plasmid which
expressed the gene peripherin 2 (Prph2) to the retina of
Prph2
+/- mice, which have a phenotype of slow retinal
degeneration [104,105]. SRT injection of CK30-PEG-
Prph2 nanoparticles significantly reduced retinal degen-
eration in Prph2
+/- mice, and sustained elevated Prph2
gene expression for up to 4 months. These promising
preclinical data suggest that CK30-PEG nanoparticles
could be developed for safe and effective gene therapy in
the retina. Moreover, CK30-PEG nanoparticle-mediated
gene therapy was safe and effective in clinical studies in
cystic fibrosis patients [106]. Thus, CK30-PEG nanoparti-
cles could potentially be a safe and effective tool for gene
therapy-based approaches to treat neovascular disease in
the retina. For instance, CK30-PEG nanoparticles could
be utilized to deliver compacted non-viral DNA vectors
encoding anti-angiogenic factors to the retina or RPE in
an effort to inhibit RNV or CNV, respectively.
Nanoparticles in Peptide and Drug Delivery
Therapeutic agents, including peptides, small molecule
drugs, antibodies, and aptamers, can be formulated into
nanoparticle-based DDS to improve therapeutic effi-
ciency by increasing and prolonging bioavailability. The
most simple nanotherapeutic agents are generated by
condensing a therapeutic agent into nanoparticles using
PEG or lipids. Thus, Macugen® is considered as a
nanotherapeutic, since it is formulated using PEGylation
to condense the drug into nanoparticles for enhanced
drug delivery. Nanoparticle-based DDS can be especially
helpful for drug molecules which have limited solubility
or significant cytotoxic effects, such as the small mole-
cule drug TNP-470, an analog of fumagillin [107].
TNP-470 is a very potent and effective angiogenic inhi-
bitor, and in early studies it was very effective as an anti-
tumor agent in several types of animal tumor models
[107-112]. In human clinical trials, TNP-470 appeared to
be an effective therapy for Kaposi’s sarcoma, non-small-
cell lung cancer, renal carcinoma, and prostate tumors
[107-112]; however, clinical trials were terminated when
TNP-470 elicited neurotoxic effects, including short-term
memory loss, seizures, dizziness, and decreased motor
coordination. TNP-470 is so small that it could easily
penetrate the blood-brain-barrier (BBB) to elicit these
effects. Initial attempts to reformulate TNP-470 to block
penetration of the BBB resulted in a drug formulation
with very transient bioavailability [113]. Recently, a nano-
technology-based DDS was developed for TNP-470 in
which TNP-470 is conjugated to a di-block copolymer of
monomethoxy-PEG-PLA, which self-assembles into nano-
micilles of approximately 20 nm diameter [114]. This new
formulation, named Lodamin, can be orally administered
to effectively treat melanoma and lung cancer in animal
models, with no evidence of BBB penetration or neuro-
toxicity. An ongoing preclinical study is evaluating the
effects of Lodamin in a laser-induced CNV mouse model
[115]. Lodamin was administered either by a daily oral
dose of 15 mg/kg body weight, or as a single IVT injection
of 100 μgo r3 0 0μg. Therapeutic outcome was assessed at
14 days post-IVT injection or on the fourteenth consecu-
tive day of daily oral treatment. Oral dosing was nearly as
effective as a single IVT injection, as both oral dosing and
IVT injection resulted in significantly reduced VEGF levels
and a 70- 75% regression of CNV lesion size [115]. Thus,
Lodamin is an example of how a small molecule anti-
angiogenic drug can be reformulated with very simple
nanotechnology-based DDS to alter drug pharmacoki-
netics and thereby greatly enhance therapeutic benefits
and reduce toxic side effects.
A PLGA nanoparticle formulation of PEDF peptide
was recently evaluated as a therapeutic agent in a mouse
model of retinal ischemia [116]. The PLGA-PEDF nano-
particles were directly compared to treatment with
PEDF peptide alone. Retinal ischemia rapidly induces
retinal ganglion cell (RGC) death, and leads to thinning
of the retina as apoptosis occurs in other retinal cell
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or PEDF peptide alone significantly reduced RGC cell
death; however, the PLGA-PEDF nanoparticles were
significantly more effective. Furthermore, the PLGA-
PEDF nanoparticles provided enhanced protection
against RGC apoptosis for up to 7 days post-injection,
whereas the PEDF peptide alone was only effective for
up to 2 days. This study highlights how nanoparticle
formulations can enhance and prolong the efficacy of a
peptide-based drug. Furthermore, this suggests that a
PLGA-PEDF peptide nanoparticle formulation could be
therapeutically effective in treating retinal neovascular
disease.
Nanoparticles for Targeted Drug Delivery
Nanoparticle carriers can greatly increase cell tropism
and cell transfection efficiency; however, this can
increase the non-specific uptake by non-target cells,
including engulfing macrophages, which may result in
decreased drug delivery to the target cell populations
and increased drug side effects. Thus, modifying nano-
particles with cell-specific targeting agents can greatly
enhance drug efficacy and reduce aberrant side effects.
The nature of the nanoparticle formulation process
allows for precise and stepwise synthesis of nanoparticle
therapeutic agents. Nanoparticles that encapsulate a
therapeutic agent can be constructed to carry various
types of molecules on their external surface in order to
target drug delivery to specific cell types. Moreover,
more than one therapeutic agent can be combined into
multi-layered nanoparticles to create a single nanothera-
peutic agent which possesses synergistic therapeutic
activity. Recent efforts to develop multi-component
nanoparticle DDS which are specifically aimed at
improving drug delivery to the retina and to neovascular
retinal capillary endothelial cells are reviewed below.
Targeting Neovascular Endothelial Cells
Proliferating, neovascular endothelial cells up-regulate
the expression of cell surface markers, such as intercel-
lular adhesion molecule 1(ICAM1) and avb3 and avb5
integrins [117]. Antibodies or peptides designed to bind
to these markers can be used to target drug delivery
specifically to neovascular endothelial cells. The huma-
nized monoclonal anti-avb3 integrin antibody known as
etaracizumab (Abegrin®, MedImmune LLC) is already in
clinical trials for cancer therapy, as it is expected to tar-
get tumor neovascularization [118,119]. Extracellular
matrix proteins which bind to integrins contain argi-
nine-glycine-apartic acid (RGD) motifs. Synthetic cyclic
and linear RGD peptides can bind to avb3 and avb5
integrins to mediate cellular uptake [117]. Various RGD
peptides have been widely used in preclinical cancer stu-
dies to target tumor vasculature, and a cyclic RGD
peptide which specifically binds both avb3 and avb5
integrins, Cilengitide (Merck) is in clinical trials for can-
cer therapy [120]. An anti-ICAM1 antibody has pre-
viously been conjugated to liposomes to generate
immunoliposomes with enhanced endothelial cell uptake
activity in vitro [121]. A peptide domain cyclo(1,12)
PenITDGEATDSGC (cLABL) from leukocyte function-
associated antigen-1 binds with high affinity to ICAM1,
and ICAM1 expressing endothelial cells have increased
uptake of PLGA-PEG nanoparticles conjugated with
cLABL [122]. These antibodies and peptides are exam-
ples of targeting moieties that could be combined with
nanoparticle-based DDS to treat neovascular disease in
the retina.
A novel integrin-binding peptide (DFKLFAVYIKYR)
known as C16Y, was derived from laminin-1, and func-
tions independently as an integrin antagonist to inhibit
angiogenesis [123]. In a laser-induced CNV rodent
model, IVT injection of the C16Y peptide incorporated
into PLA/polyethylene oxide(PEO) nanoparticles (PLA/
PEO-C16YNP) was more effective than C16Y peptide
alone for reducing CNV lesion size [124]. Moreover, the
PLA/PEO-C16YNP had prolonged bioavailability com-
pared to the C16Y peptide alone, demonstrating how
nanoparticle formulations can enhance the bioactivity
and bioavailability of therapeutic agents designed to
target neovascular endothelial cells.
An ongoing preclinical study in mice utilizes quantum
dot nanocrystals (QD) to generate ICAM1-targeted
nanocarriers (ITNs) by conjugating ICAM1 antibodies
to the external surface of the QD [125]. ITNs specifi-
cally target proliferating, neovascular endothelial cells,
which selectively express ICAM1 on their cell surface.
The ITNs, which are smaller than 200 nm, bind
to ICAM-1 on the neovascular ECs, which leads to
clathrin-mediated endocytosis of the ITNs. The ITNs
can encapsulate various therapeutic agents, such as
siRNA, peptides, and small molecules, and deliver those
cargoes to the neovascular endothelial cells.
In addition to the use of nanocarriers as drug delivery
agents, gold nanoparticles can also be used for photo-
thermal-induced cell killing. Gold nanoparticles can be
activated by a low-energy near-infrared laser to produce
heat, which causes cell damage and death. This type of
photothermal therapy has previously been explored for
cancer treatment [126-128]. An ongoing preclinical
study is investigating the use of gold nanoparticles for
the photothermal treatment of CNV in AMD. In an
effort to target neovascular endothelial cells in CNV
lesions, PEG-coated gold nanorods of 45 nm × 15 nm
were conjugated with RGD peptides (Gold-RGD-NP)
[61]. Following intravenous administration in a CNV
mouse model, Gold-RGD-NPs were localized in intracel-
lular vesicles of retinal endothelial cells. Subsequently,
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endothelial cells containing Gold-RGD-NPs, whereas
nearby cells which were not laser-treated and/or did not
contain gold nanoparticles remained viable. The sur-
rounding tissue is unharmed because the low-energy
near-infrared laser does not generate heat unless it is
focused onto the gold nanoparticles. Moreover, the heat
that is generated by the gold nanoparticles is minimal
and induces apoptosis, and not rapid necrosis, of neo-
vascular endothelial cells. Although this study is in very
early preclinical stages, it indicates that gold nanoparti-
cle-mediated photothermal therapy could be a safe and
effective treatment for CNV lesions in AMD and thus
warrants follow-up studies. In future studies, gold
nanorods could also be conjugated with different agents
to target endothelial cells, such as antibodies which bind
to the neovascular endothelial cell surface markers
ICAM1 or avb3 integrin.
Enhancing Ocular Delivery
A recent study evaluated if nanoparticles, designed to
target the retina and neovascular lesions, could be admi-
nistered intravenously and result in effective gene delivery
to CNV lesions [63]. This study utilized the Flt23K DNA
plasmid, which encodes the anti-VEGF intraceptor, a
recombinant protein that includes VEGF-binding domains
2a n d3o fV E G F R - 1c o u p l e dt ot h ee n d o p l a s m i cr e t i c u -
lum (ER) retention signal sequence Lys-Asp-Glu-Leu
(KDEL) [129]. The anti-VEGF intraceptor is designed to
bind to VEGF as it is synthesized in the ER to sequester
VEGF and inhibit VEGF secretion. Previous studies have
shown that the Flt23K plasmid can inhibit hypoxia-
induced VEGF expression and corneal neovascularization
in vivo [129]. The most recent study encapsulated the
Flt23K plasmid into PLGA nanoparticles, which were con-
jugated with either transferrin (Tf), RGD peptide, or both
in order to facilitate delivery to retinal CNV lesions [63].
Transferrin was chosen for as a targeting peptide because
the retina expresses transferrin receptors, and AMD reti-
nas have increased transferrin uptake [130]. The Tf/RGD-
targeted nanoparticles ranged in size from 380-450 nm.
Within 24 hours of intravenous administration, Tf/RGD-
targeted nanoparticles were delivered specifically to CNV
lesions in the retina, and were not present in the contralat-
eral control non-CNV retina. A much smaller amount of
the non-targeted nanoparticle was also delivered to CNV
lesions, likely due to the non-specific effect of vascular
leakage. Importantly, intravenous administration did not
lead to any nanoparticle detection in the brain. Nanoparti-
cles were detected in non-retinal tissues, including the
liver, lung, heart, kidney, and spleen; however, Tf/RGD-
targeting did not increase nanoparticle delivery to these
tissues. Thus, conjugation of Tf and/or RGD specifically
increased delivery to neovascular lesions in the retina.
Only Tf/RGD-functionalized nanoparticles, and not
unconjugated nanoparticles, were expressed in the RPE
cell layer. RGD conjugation also produced significant gene
delivery to retinal endothelial cells, whereas Tf-conjugated
nanoparticles were targeted more generally to the retina
than to the retinal endothelial cells. Impressively, the intra-
venous administration of either Tf- or RGD-functionalized
nanoparticles delivered enough nanoparticle to the CNV
lesions to block CNV-induced up-regulation of VEGF pro-
tein in the retina and RPE-choroid and to significantly
reduce the size of CNV lesions [63].
Preclinical studies have recently demonstrated that a
synthetic cationic cell-penetrating peptide can facilitate
the delivery of therapeutic agents, including peptides,
small molecules, siRNA, and DNA, to the retina and
RPE by IVT and SRT injection, respectively [95,131].
This peptide for ocular delivery (POD), [CGGG(ARK-
KAAKA)4], was modified with PEG to generate nano-
particles which compact plasmid DNA into 120-150 nm
nanoparticles [96]. Subretinal injection of PEG-POD-
DNA nanoparticles resulted in DNA expression in RPE
cells, and was 200-fold more efficient in transfecting
RPE cells than naked DNA plasmid [96]. PEG-POD-
DNA plasmid has since been used to deliver a neuro-
trophic factor to the mouse retina, which resulted in
reduced light damage-induced retinal degeneration
[132]. Thus, PEG-POD nanoparticles have the potential
to be adapted for the delivery of anti-neovascular thera-
peutic agents to the retina and RPE for the treatment of
RNV and CNV.
Conclusion
The treatment of retinal neovascular disease has been
greatly improved by anti-VEGF therapies which have
been developed over the past decade. However, frequent
IVT injections are necessary for efficient and prolonged
delivery of these therapeutic agents to the retina. Recent
preclinical studies demonstrate that nanoparticle-based
DDS can enhance bioactivity and prolong bioavailability
of therapeutic agents in the retina. Moreover, efforts are
underway to develop multi-component nanoparticle
DDS to specifically target drug delivery to the retina,
and more specifically to retinal neovascular endothelial
cells. Thus, nanoparticle-based DDS are likely to have a
large impact on the future treatment of neovascular dis-
ease in the retina.
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